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Abstract
Introduction: Short PLUNC1 (SPLUNC1) is the founding member of a family of proteins (PLUNCS) expressed in the upper
respiratory tract and oral cavity, which may function in host defence. It is one of the most highly expressed genes in the upper
airways and the protein has been detected in sputum and nasal secretions. The biology of the PLUNC family is poorly
understood but in keeping with the putative function of the protein as an immune defence protein, a number of RNA and protein
studies have indicated that SPLUNC1 is increased in inflammatory/infectious conditions such as Cystic Fibrosis (CF), COPD and
allergic rhinitis.
Methods: We used immunohistochemistry to localise SPLUNC1 in lung tissue from patients with CF and a range of other lung
diseases. We used a range of additional markers for distinct cell types to try to establish the exact site of secretion of SPLUNC1.
We have complemented these studies with a molecular analysis of SPLUNC1 gene expression in primary human lung cell
cultures and isolated inflammatory cell populations.
Results: In CF, expression of SPLUNC1 is significantly elevated in diseased airways and positive staining was noted in some of
the inflammatory infiltrates. The epithelium of small airways of CF lung exhibit significantly increased SPLUNC1 staining
compared to similar sized airways in non-CF lungs where staining is absent. Strong staining was also seen in mucous plugs in the
airways, these included many inflammatory cells. No alveolar epithelial staining was noted in CF tissue. Airway epithelial staining
did not co-localise with MUC5AC suggesting that the protein was not produced by goblet cells. Using serial sections stained
with neutrophil elastase and CD68 we could not demonstrate co-localisation of SPLUNC1 with either neutrophils or
macrophages/monocytes, indicating that these cells were not a source of SPLUNC1 in the airways of CF lungs. No change in
staining pattern was noted in the small airways or lung parenchyma of other lung diseases studied including, COPD, emphysema
or pneumonia where significant NE and CD68 staining was noted. Cultures of primary tracheobronchial epithelial cells were
analysed by RT-PCR and showed that pro-inflammatory mediators did not induce expression of SPLUNC1. We have also shown
that SPLUNC1 gene expression was not seen in isolated human mononuclear cells, macrophages or neutrophils.
Conclusion: These studies show that SPLUNC1 is specifically and significantly increased in the small airways of lungs from
patients with CF. They further suggest that it is the airway epithelium that is responsible for the increased levels of SPLUNC1
in CF and not inflammatory cells; this could be a defensive response to the infectious component of the disease.
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Background
SPLUNC1 is the founder member of the PLUNC family of
putative innate immune molecules, and is highly
expressed in the epithelium of the upper respiratory tract,
nasopharynx and submucosal glands [1]. The mouse
orthologue of SPLUNC1, Palate Lung Nasal Clone
(plunc) was first identified as a molecule expressed in the
developing mouse oral cavity around the time of palatal
shelf closure; it is expressed in the nasal epithelium of the
mouse embryo and the trachea and bronchi of adult
mouse lung [2]. Using a systematic, bioinformatic and
expression study we subsequently identified the wider
PLUNC family of nine human genes located on chromo-
some 20 [3,4]. PLUNC genes are expressed in overlapping
patterns predominantly in the upper respiratory tract,
nasal passages and oral cavity [1,3]. All PLUNC proteins
contain signal peptides suggesting they would be secreted
into the extracellular fluids bathing these locations. Due
to the structural similarity between PLUNCs and the lipid/
LPS binding, innate defence proteins lipopolysaccharide
binding protein (LBP) and Bactericidal/permeability-
increasing protein (BPI), we, and others, have hypothe-
sised that PLUNCs may function in the innate immune
defence of the respiratory tract. [3-7]. However, direct
proof of such a host defence function remains to be pub-
lished. SPLUNC1 mRNA has been identified in tracheal
epithelium [8,9] and in sub-mucosal glands and ducts [9].
The protein was localised to the same sites [10], and our
previous studies have shown that the submucosal glands
of the upper respiratory tract and the minor mucosal
glands of the oropharynx appear to be the major sites of
protein localisation [11]. These same studies also show
that expression of SPLUNC1 is limited to a few non-cili-
ated epithelial cells of the upper airways and is absent
from small airways and from peripheral lung [11]. This
contrasts to the situation in the mouse where in situ
hybridisation suggests that splunc1  is expressed in the
majority of epithelial cells in the trachea and main bron-
chi [1,8]. SPLUNC1 is one of the major proteins secreted
from differentiated human tracheo-bronchial epithelial
cells in culture [10] and has been identified as a highly
expressed gene in such cells in a number of studies
[12,13].
Cystic fibrosis (CF) is an autosomal recessive disorder
caused by mutations of the CF trans-membrane regulator
(CFTR) gene [14,15]. The genetic defect in CF leads to
abnormal epithelial chloride and water transport and this
results in increased viscosity of, and subsequent decreased
clearance of, airway secretions. This in turn affects airway
defence resulting in chronic lung infection [16]. Inflam-
matory cells recruited in response to this active infection
lead to a state of chronic airway inflammation. CF lung
disease is therefore characterised by plugging of airways
associated with persistent bacterial infection and massive
neutrophil infiltration [16]. The CF lung becomes infected
with a distinctive bacterial flora, including Pseudomonas
aeruginosa,  Staphylococcus aureus, and organisms of the
Burkholderia cepacia complex which are associated with
plugging of the small airways. This plugging directly con-
tributes to the impaired lung function seen in CF, leading
to respiratory failure. CF lung disease is largely restricted
to the airway compartment of the lung with the paren-
chyma being largely unaffected. There is no effective treat-
ment for CF and patients with the disease will ultimately
require lung transplantation [16]. Innate immune
defences of the lung are significantly impaired in CF as a
consequence of a combination of factors, including phe-
notypic alterations of the airway epithelium, the elevated
viscosity, alterations in the ionic strength and pH of the
airway lining fluid and the increased levels of inflamma-
tory cells present in the inflamed tissues [16]. The defects
in innate defences become self-sustaining, because the
inflammatory cell derived proteases, including neutrophil
elastase (NE), released from the abundant mass of
recruited cells, specifically degrade many host defence
proteins [17].
As a putative innate defence molecule expressed in the
upper airways and in submucosal glands, SPLUNC1 could
potentially be involved in combating the chronic infec-
tions seen in CF and other lung diseases with an infectious
component. Previous studies have shown that SPLUNC1
is elevated in the sputum of patients with COPD [9].
Although similar studies have not been shown in CF, a
proteomic study has shown that CF nasal epithelial cells
contain increased levels of SPLUNC1 [18] and molecular
studies have shown that CF epithelial cells appear to
express abundant SPLUNC1 [12]. In this paper we dem-
onstrate that CF airways specifically express abundant
SPLUNC1 and show that this elevated protein expression
is not the product of the inflammatory cells that accumu-
late in the disease.
Methods
Immunohistochemistry
The tissue used in this study was collected with ethical
approval only on a fully anonymised basis and thus we
have no further patient details. Serial sections were cut
from formalin-fixed and paraffin-embedded tissue as
described [11]. For normal tissues, sections were taken so
as to be as representative of normal architecture as possi-
ble, although as all tissues were removed for medical rea-
sons there was some evidence of disease in some sections.
Sections from the major bronchi and peripheral lung were
cut from 10 cases of normal lung and similar samples
were also obtained from 10 patients with CF who were
undergoing lung transplantation. We also studied 10
cases from patients with emphysema and two cases from
patients with pneumonia. The histologically "normal"Respiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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and emphysematous samples were resections taken dur-
ing surgery for cancer, where no tumour tissue was seen to
be present, the CF tissue was removed during the course
of transplantation and the pneumonia tissue was col-
lected during post-mortem. The slides were treated with
2% hydrogen peroxide in methanol for 20 minutes to
quench endogenous peroxidase.
The following antibodies were used in this study: A poly-
clonal antibody raised against human SPLUNC1 [10]
(final dilution 1:300); a polyclonal antibody to human
mucin 5AC (MUC5AC, a gift from David Thornton, Uni-
versity of Manchester, UK; final dilution 1:250); mono-
clonal antibodies to tryptase, CD68 and neutrophil
elastase purchased from Dako (1:1200, 1:400 and 1:300
respectively). A standard antigen retrieval procedure using
tri-sodium citrate in a microwave for 8 minutes was used
for the MUC5AC, tryptase and CD68 antibodies. The spe-
cificity of the SPLUNC1 antibody has previously been
shown by western blotting using a number of recom-
binant PLUNC proteins [11]. Sections were incubated
with 100% normal serum (goat for polyclonal antibodies,
horse for monoclonal antibodies) at room temperature
for 30 minutes and then at 4°C overnight with the anti-
bodies diluted as indicated above with 100% normal
serum. Rabbit or mouse IgG (DAKO) was used as a nega-
tive controls on replicate slides. A Vectastain Elite ABC kit
(Vector Laboratories) containing an appropriate biotin-
labelled secondary antibody was used according to the
manufacturer's instructions. Peroxidase enzymatic devel-
opment was performed using, a Vector NovaRed substrate
kit resulting in red staining in positive cells. Sections were
counterstained with haematoxylin, dehydrated to xylene
and mounted in DPX.
Tissue culture, Cell isolation, RNA extraction and RT-PCR
Human tracheobronchial epithelial (TBE) cell cultures
were prepared by methods described previously [19]
using trachea and bronchi from lungs that were not
deemed suitable for transplant through the Life Alliance
Organ Recovery Agency of the University of Miami and
approved by the local institutional review board. Cells
were grown in a medium containing 50% DMEM and
50% LHC basal medium (Biosource International,
Camarillo, CA, USA) supplemented with hormones and
trace elements as described [19]. Upon reaching conflu-
ence (after 3–7 d), the medium from the apical surface
was removed, leaving the top surface exposed to air (air-
liquid interface cultures, ALI). To study the effect of retin-
oic acid (RA) on the expression of SPLUNC1, normal RA
(50 nM) was removed from the medium of fully differen-
tiated TBE cells after 14 days exposed to air. To study the
effects of pro-inflammatory mediators on SPLUNC1 gene
expression, TBE cells were stimulated with 25 ng/ml of IL-
1β or TNFα (both from R & D Systems, Inc, Minneapolis,
MN, USA) for 6, 24 or 48 hours prior to harvest. Stimula-
tions for RNA analysis were performed on cultures from
three individual donors.
Human peripheral blood neutrophils, mononuclear
(MNC) cells, monocytes and T and B cell enriched cell
populations from normal healthy donors, were isolated
by density gradient centrifugation and cultured as previ-
ously described [20]. Monocyte-derived macrophages
were differentiated from monocytes on tissue culture plas-
tic using standard protocols [21]. A SPLUNC1 expressing
CHO cell line was generated from a full-length human
SPLUNC1 expression clone [11] using the Flp-in system
(Invitrogen).
Total RNA was isolated as previously described [1].
Reverse transcription was also performed as previously
described [22] in a total volume of 25 μl using an oligo-
dT primer and 1 μg of total RNA. PCR reactions were per-
formed using 1 μl of each reaction product and the follow-
ing primer pairs. SPLUNC1F 5' ATG CCC TCA GCA ATG
GCC TGC T 3', SPLUNC1R 5' GTG AGG CTG TCC AGA
AGA CC 3': WFDC2 F: 5' CGG CTT CAC CCT AGT CTC AG
3'; WFDC2 R: 5' AAA GGG AGA AGC TGT GGT CA 3';
Elafin F: 5' ACC TTC CTG ACA CCA TGA GG 3'; Elafin R:
5' GAT GAG AGA GGC AGC TCC AG 3'; BCL2A1 F 5' GCC
ACC ATG ACA GAC TGT GAA TTT GGA TAT 3', BCL2A1R
5' TCA ACA GTA TTG CTT CAG GAG AGA 3': Primer pairs
were designed using Primer3 [23] and were designed to
cross intro/exon boundaries. 30 cycles of the following
program (94°C for 1', 60°C for 2' and 72°C for 3') gener-
ated the appropriately sized products, which were
resolved on 2% TAE agarose gels, stained with ethidium
bromide and photographed. Representative samples of
each were directly cloned in TOPO pCRII (Invitrogen)
and sequenced.
Results
On the basis of a number of reports which have shown
that SPLUNC1 may be elevated in inflammatory lung dis-
ease, we used immunohistochemistry to study SPLUNC1
protein expression in chronically inflamed lung tissue
from patients with a range of conditions including those
who had undergone transplantation for CF. We have pre-
viously shown that SPLUNC1 is predominantly localised
in the minor mucosal glands of the oro- and naso phar-
ynx, whilst in the airways SPLUNC1 is found in a few epi-
thelial cells of the large airways but is most strongly
expressed in the submucosal glands [11] (Figure 1A). In
histologically "normal" tissue from patients undergoing
lobectomy surgery, SPLUNC1 staining is not seen in
smaller airways (Figure 1B and 1C). In large airways of
subjects with CF, the site or level of staining of SPLUNC1
within the bronchiolar epithelial cells or the submucosal
glands was similar to that of normal lungs (results notRespiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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SPLUNC1 is increased in the small airways of CF lung Figure 1
SPLUNC1 is increased in the small airways of CF lung. Immunohistochemical localisation of SPLUNC1 was performed 
as described in the materials and methods sections. Sections show submucosal gland staining in "normal" human airways (A) 
and a lack of staining in the epithelium of smaller airways (B, C, an enlarged inset of B). Expression of SPLUNC1 is increased in 
cases of CF (D-H) where staining was predominantly found in the epithelial cells of the smaller airways and also within the 
inflammatory cell containing mass within the plugged lumens. SPLUNC1 did not co-localise with MUC5AC (I). There was no 
staining within the peripheral lung tissue of cases of CF (J). Cases of emphysema (K) and bacterial pneumonia (L) also did not 
exhibit SPLUNC1 staining.Respiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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shown). However, the situation in smaller airways within
the peripheral lung of the CF cases was markedly different
(Figure 1D, E, F, G, H). In this study we define small air-
ways as those without cartilage or submucosal glands. In
all 10 cases there was significant staining in the abnormal
(hyperplastic) epithelium. This staining appeared to be
restricted to the epithelium (Figure 1D, E, F, G, H) and
contrasts greatly to the situation seen in similar sized air-
ways from CF-disease free lung (Figure 1B). Epithelial
staining appeared to be present towards the apical surface
of the cells and along the epithelial surface. In addition to
the greatly increased staining seen within the epithelium,
the inflammatory plugs within the airway lumen were
also found to stain strongly for SPLUNC1 (Figure 1D, E,
G) suggesting the protein is secreted into the lumen of
these diseased airways. Although significant numbers of
inflammatory cells were present in these sections it was
not immediately clear if these cells were expressing
SPLUNC1. SPLUNC1 was not present in the increased
mucous cell population found in some regions of the dis-
eased airways (Figure 1H). This observation was con-
firmed when serial sections were stained with the goblet
cell marker MUC5AC (Figure 1I). These results clearly
show that SPLUNC1 immunoreactivity is increased in the
small airways of the lungs of patients with CF and further-
more suggest the protein is secreted into the luminal con-
tents of the diseased lung. The specificity of this was
highlighted by the observation that peripheral lung sec-
tions from the same CF patients were uniformly negative
(Figure 1J), as were additional sections from patients with
emphysema (Figure 1K) and bacterial pneumonia (Figure
1L). In all of these conditions a significant number of
inflammatory cells (predominantly neutrophils and
monocytes/macrophages) were found and these did not
appear to stain with SPLUNC1.
As BPI, one of the paralogues of SPLUNC1, is highly
expressed in neutrophils [24] and because it has recently
been suggested that SPLUNC1 may be present in periph-
eral blood neutrophils [25] we examined this expression
in more detail. Initially we took isolated populations of
inflammatory cells and used them for a series of RT-PCR
experiments. RNA isolated from peripheral blood neu-
trophils, mononuclear cells, B and T cells, monocytes and
monocyte derived macrophages (MDMs, both mock
infected and infected with Neisseria meningitidis MC58)
were all negative for SPLUNC1 expression (Figure 2,
upper panel). A strong positive signal was seen in samples
from nasal septal epithelium and a stable CHO cell line
expressing human SPLUNC1. All of the inflammatory cell
samples were shown to be positive for the apoptosis regu-
lator Bcl2A1 (Figure 2, lower panel); this is expressed in
leukocytes [26]. Our results suggest that neutrophils and
other leukocytes do not express SPLUNC1 RNA. To
exclude the possibility that SPLUNC1 RNA is present only
in immature neutrophils as they undergo differentiation
in the bone marrow and prior to release into the circula-
tion we examined the data set of Theilgaard-Monch et al
[27] in which the differentiation programme of neu-
trophils was examined by expression array. In these stud-
ies no SPLUNC1 transcripts were detected at any stage of
differentiation in three individual experiments using dif-
ferent donors (results not shown). This observation was
subsequently confirmed by the failure to detect SPLUNC1
mRNA in similar samples by northern blotting (Jack Cow-
land, personal communication). To further confirm the
lack of SPLUNC1 in inflammatory cells within in the CF
lung we stained serials tissue sections with SPLUNC1,
neutrophil elastase (as a marker for neutrophils) and
CD68 (as a marker for macrophages/monocytes) (Figure
3). In these studies it can clearly be seen that the staining
for SPLUNC1 is either within the occluded lumen or
within the epithelial cells (Figure 3A) whereas CD68 (Fig-
ure 3B) and neutrophil elastase (Figure 3C) are predomi-
nantly seen within the inflammatory cell mass in the
airway lumen or in isolated cells either infiltrating the epi-
thelium or within the sub epithelial layer. The lack of
SPLUNC1 staining in sections of tissue from bronchial
pneumonia (Figure 3D) contrasts strikingly with the
intense staining of both macrophages and neutrophils
(Figure 3E, F). These results suggest that the increased pro-
duction of SPLUNC1 in CF small airways was unlikely to
have arisen from inflammatory cells.
As the CF lung is a hyper-inflammatory environment, we
studied SPLUNC1 gene expression in tracheobronchial
epithelial cells, as a surrogate for the situation seen in vivo,
to determine whether it was influenced by classical pro-
inflammatory cytokines. SPLUNC1 is highly expressed in
tracheobronchial epithelial cells when they are differenti-
ated at an air liquid interface [9,10,13]. We studied the
potential of these cells to increase SPLUNC1 mRNA fol-
lowing treatment with IL-1β for 6, 24 and 48 hours.
Although there is a level of variability of SPLUNC1 expres-
sion between cells isolated from different donors, levels of
SPLUNC1 mRNA were not elevated by IL-1β treatment at
any of the time points studied (Figure 4A). We could
show, however, that these stimulations did induce expres-
sion of the gene for the antiproteinase, Elafin and this is
consistent with our previous studies [28]. Also consistent
with our previous results the related host defence mole-
cule WFDC2 was not induced in these cells. TNFα treat-
ment of the same cultures failed to induce expression of
SPLUNC1 (results not shown). We were also unable to
show any induction of SPLUNC1 mRNA in similar cell
culture experiments following exposure to either bacterial
lipopolysaccharide (LPS) or human neutrophil elastase, a
neutrophil derived protein that is abundant in the CF lung
(results not shown). These results suggest that the increase
in SPLUNC1 staining in the epithelium of the CF airwayRespiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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is not due to a transcriptional effect of cytokines or pro-
inflammatory mediators acting directly on the SPLUNC1
gene. It may, however, be due to phenotypic alterations of
the epithelial cell populations in the airways leading to a
greater number of SPLUNC1 positive cells being present.
In support of this suggestion we have shown that TBE cells
cultured at the ALI require a source of RA in the culture
media to maintain continued levels of SPLUNC1 expres-
sion (Figure 4B). Removal of RA from the basal media of
differentiated cell cultures leads to a progressive loss of
SPLUNC1 over an 18-day period. We have previously
shown that the withdrawal of RA leads to an increase in
expression of Elafin and a loss of MUC5AC [28]; this is
known to correspond with a return to a squamous (de-dif-
ferentiated) cell phenotype.
Discussion
Since our original description of the expression pattern of
human SPLUNC1 gene being limited to the upper respira-
tory tract [1] a number of other expression studies have
shown that it is highly expressed in the tracheobronchial
epithelium of the human respiratory tract. A number of
proteomic and protein studies have shown that the pro-
tein can be detected in nasal secretions [29-32] where lev-
els may be altered by chemical injury [29,30] and viral
infection [33]; it has also been studied in sputum, where
levels appear to be increased in COPD [9]. A large-scale
EST sequencing and characterisation study appeared to
show that the SPLUNC1 gene was more highly expressed
in airway epithelial cells from CF patients compared to
non-CF patients [12]. Additionally, CF nasal epithelial
cells have also been shown to contain increased levels of
SPLUNC1 compared to normals [19].
More recently we performed an extensive study of the
localisation of SPLUNC1 protein in normal human tis-
sues from the respiratory tract, oral cavity and nasophar-
ynx [11]. These studies confirmed previous findings that
the gene was expressed in submucosal glands and some
cells of the tracheal epithelium but extended our observa-
tions to show that the protein was expressed in multiple
minor mucosal glands from the nasal antrum and
throughout the oral cavity including glands localised in
the tongue and adjacent to tonsils. This study also showed
that small airways, that is those which contain neither car-
tilage nor submucosal glands and peripheral lung tissue,
SPLUNC1 is not expressed in neutrophils, monocytes or macrophages Figure 2
SPLUNC1 is not expressed in neutrophils, monocytes or macrophages. Expression of SPLUNC1 was investigated by 
the use of RT-PCR with exon spanning primer pairs as described in the materials and methods section. Total RNA from B and 
T cells, neutrophils, monocytes, mononuclear cells and macrophages (either mock treated or infected with Neisseria meningi-
tidis mc58) as well as positive control tissues (nasal epithelium and SPLUNC1-CHO cells), were used as template. The negative 
controls were a negative reverse transcription reaction performed in the absence of RT enzyme and a PCR reaction per-
formed without Taq polymerase. Primers to the myeloid enriched anti apoptotic gene Bcl2A1 were used as a positive control 
for all samples.Respiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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do not express SPLUNC1 [11]. In striking contrast to the
situation described for normal lung, our present study has
clearly shown that SPLUNC1 is significantly increased in
the small airways of patients with advanced CF. The spe-
cificity of this observation is shown by the fact that similar
alterations are not seen in patients with other lung condi-
tions, including bacterial pneumonia and emphysema, as
well as tuberculosis (results not shown). It is also note-
worthy that this change in abundance of SPLUNC1 in CF
is found at sites where the protein is not normally seen.
Our studies suggest that this is likely due to an increase in
epithelial production of the protein as we have been una-
ble to show that SPLUNC1 is present in the inflammatory
cells that accumulate within the diseased airways in this
condition. Indeed no SPLUNC1 staining is seen in the
peripheral lung tissue of the same CF patients nor in the
peripheral lung of patients with bacterial pneumonia,
both of which contain significant numbers of neutrophils,
monocytes and macrophages. We were also unable to
show that SPLUNC1 mRNA was present in isolated
human neutrophils, monocytes or monocyte-derived
macrophages. As the transcription of many neutrophil
gene products is largely restricted to the period in which
the cells are developing within the bone marrow [27,33]
we also looked at expression in highly purified cell popu-
lations from this source. Again, these samples were nega-
tive for SPLUNC1 mRNA. On the basis of these
observations we suggest that SPLUNC1 is not a significant
product of inflammatory cells in the diseased airway.
We have been also been unable to show that treatment of
airway cells with the classical inflammatory mediators, IL-
1β and TNFα (nor indeed bacterial LPS or hNE) affects
SPLUNC1 gene expression suggesting that the gene is not
transcriptionally regulated by these factors. This is consist-
ent with a recent report showing a similar lack of induc-
tion of the SPLUNC1 in nasal epithelial cell cultures
treated with the same stimuli [34]. On the basis of these
results we would suggest that the increased SPLUNC1 that
is seen in the epithelial cells of the CF airways is the result
of a phenotypic alteration in the epithelium itself. It is
well known that airway epithelial phenotypic changes are
associated with changes in gene expression and this has
been well studied in tissue culture models. Our data show
that SPLUNC1 gene expression in airway epithelium in
culture requires a continued exposure to RA as this main-
tains a mucociliary phenotype. This observation is con-
sistent with other published data [9,10], including the
study of Ross et al, that shows that SPLUNC1 is one of the
most differentially expressed genes during this differenti-
ation process [13]. In our cultures we have shown that
SPLUNC1 is present in non-ciliated cells (results not
shown) but in vivo it is clear that the protein is only
expressed in a limited number of epithelial cells [11] and
is not located in goblet cells.
Two significant questions arise from our observations.
Firstly, what is the consequence of this alteration in
SPLUNC1 production in CF and secondly, are levels of
SPLUNC1 increased in less severe CF lung disease? In line
with the hypothesised function of SPLUNC1 as an innate
immune defence protein, it might be expected that the
protein would be increased as a defensive response in
severe CF where the pathogenic load is markedly elevated.
It is clear that other innate defence factors are also
increased in this condition but perhaps the severity of the
inflammatory disease coupled with the significant patho-
genic load overcomes the defensive capability of the
innate immune shield. One of the major limitations of
this study is that we have only been able to obtain tissue
from patients with severe CF at the time of lung transplan-
tation. It remains to be seen if similar alterations in
SPLUNC1 localisation and expression are found in less
severe cases; this could be accomplished in future studies
by examining levels of SPLUNC1 protein in CF secretions.
SPLUNC1 is not expressed in inflammatory cells in CF or  pneumonia Figure 3
SPLUNC1 is not expressed in inflammatory cells in 
CF or pneumonia. Serial sections of lung tissue were 
stained as described in the materials and methods section. 
SPLUNC1 (A) is not found to be expressed in CD68 
expressing cells (Macrophages, B) nor in neutrophil elastase 
expressing cells (Neutrophils, C) in CF. Arrows in A point to 
the SPLUNC1 negative lumen as well as the positively stain-
ing epithelial cell layer. In sections from a case of bacterial 
pneumonia neither macrophages (E) nor neutrophils (F) 
appear to stain for SPLUNC1 (D), which is negative in this 
field.Respiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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Conclusion
These studies show that the putative innate immune mol-
ecule, SPLUNC1 is specifically and significantly increased
in the small airways of lungs from patients with CF. They
further suggest that it is the airway epithelium that is
responsible for the increased levels of SPLUNC1 in CF and
not inflammatory cells; this could be a defensive response
to the infectious component of the disease.
Abbreviations
BPI Bactericidal Permeability Increasing Protein
CF Cystic Fibrosis
Expression of SPLUNC1 in TBE cells grown at the ALI is not induced by pro-inflammatory mediators but requires continued RA  driven differentiation Figure 4
Expression of SPLUNC1 in TBE cells grown at the ALI is not induced by pro-inflammatory mediators but 
requires continued RA driven differentiation. A. TBE cells isolated from three different donors were grown at the ALI 
as described in the materials and methods section. Cells were treated for increasing lengths of time with 25 ng/ml of IL-1β 
prior to isolation of RNA. Expression of SPLUNC1 was investigated by the use of RT-PCR with exon spanning primer pairs as 
described in the materials and methods section. Primers to Elafin and WFDC2 were used as controls. B. The effect of with-
drawal of RA from the ALI growth medium was tested in TBE cells from the same three donors. ALI cells were established 
using standard grow conditions in medium containing 50 nM all trans retinoic acid (RA). After 14 days in culture RA was 
removed from the medium of one group of cells and culture was continued for an additional 18 days. RNA was harvested at 7 
and 14 days during ALI growth and 20, 26 and 32 days following RA removal for 6, 12 and 18 days respectively prior to the iso-
lation of RNA. Expression of SPLUNC1 was investigated by the use of RT-PCR with exon spanning primer pairs as described in 
the materials and methods section with primers to GAPDH serving as a positive control.Respiratory Research 2007, 8:79 http://respiratory-research.com/content/8/1/79
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CHO Chinese Hamster Ovary
COPD Chronic Obstructive Pulmonary Disease
IL-1β Interleukin-1β
LBP Lipopolysaccharide Binding Protein
LPS Lipopolysaccharide
MDM Monocyte-derived Macrophages
MNC Mononuclear Cells
MUC5AC Mucin 5AC
NE Neutrophil Elastase
PLUNC Palate Lung Nasal Clone
RA Retinoic Acid
SPLUNC1 Short PLUNC 1
TBE Tracheobronchial epithelium
TNFα Tumour Necrosis Factor α
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